Kos...also IIl said this in the report
"The Company has previously advised that no adjustments will be made to the analysis to take account of the multiplicity of outcomes, but success will be judged on consistency of the outcomes rather than inferential statistical testing."
HHmmmm very vague......
Look at drug review process in report...
Iil have not done an ind application stage 4
So they are doing a 2b trial without FDA and ind consultation....
ANP Price at posting:
3.8¢ Sentiment: Buy Disclosure: Held
